Journal · Supply chain
Where compounded GLP-1 ingredients come from: FDA's green list, salt forms, and what 20 programs disclose
Released: · Last reviewed: · By Dr. Parmis
FDA now screens imported GLP-1 active ingredients at the border and warns against semaglutide salt forms. We read 20 programs' own pages to see what they tell you about the ingredient in your vial.
None of the 16 GLP-1 telehealth programs whose pages we could read says who manufactured the active ingredient (API) in its compounded semaglutide or tirzepatide, or whether that supplier is on FDA's Import Alert 66-80 "green list." We read each program's own pages on November 10, 2026: 16 loaded, 12 offer compounded GLP-1s, and four blocked us.
Three links in the chain, and the one nobody names
A compounded GLP-1 passes through three hands before it reaches you. The telehealth program takes your order. A pharmacy compounds the vial. And somewhere upstream, a manufacturer made the raw active ingredient, called the API or bulk drug substance, that the pharmacy started from.
This piece is about that first link. Since September 2025, FDA has screened it at the border, and its consumer page warns about a specific API problem: semaglutide salt forms.
Compounded semaglutide and tirzepatide are not FDA-approved and are not generic Wegovy or Zepbound. They are made with the drug in Wegovy or Zepbound, but they are not the same product. Where that drug came from is a fair question to ask.
What the green list is, in FDA's words
FDA announced the green list on September 5, 2025. The idea is simple: GLP-1 APIs offered for import can be detained without physical examination unless the manufacturer and drug are on the list.
The current version of Import Alert 66-80 carries a published date of October 9, 2026. Here is what it says, with numbers:
- FDA evaluated 48 GLP-1 API sites through inspections or records requests. It found 21% "noncompliant," either from the records they sent or because they did not answer in time.
- FDA describes "a pattern of sites" that register as GLP-1 API makers, offer API for import, refuse records requests, then deregister, "all within a short period of time."
- The public green list has 21 firm entries. The firm names are blanked out on the public page; only the countries and drugs show. By our count: 12 in China, 3 in India, and one each in Belgium, Canada, Denmark, Ireland, Italy and Portugal.
- Semaglutide appears in 10 entries and tirzepatide in 9. The revision notes on the current version list orforglipron API added for three manufacturers.
FDA's own explanation of why this matters is the key sentence for patients. Under the alert, pharmacies compounding under section 503A "are exempt from CGMP requirements, including the requirement to ensure API used in manufacturing meets specifications for impurities or potency." So, FDA writes, there is "a heightened risk" that API quality problems would not be caught during compounding.
The list also moves. In a May 1, 2026 letter, FDA said one API firm was added to the green list on September 5, 2025, then removed on February 27, 2026 after it relabeled semaglutide bought from a facility that was not on the list.
FDA's consumer page, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (content current as of October 1, 2026), adds two limits. The alert does not apply to API from manufacturers that appear compliant, and it "does not stop the legal importation" of GLP-1 APIs from compliant makers or "create any new limits on the legal compounding of GLP-1 drugs."
The salt-form warning
The same FDA page has a section titled "Salt forms should not be used to compound semaglutide." It says some semaglutide sold by compounders "may be the salt forms," naming semaglutide sodium and semaglutide acetate. FDA calls these "different active ingredients than are used in the approved drugs" and says it is "not aware of any lawful basis for their use in compounding."
This is not new. FDA first flagged salt forms in its June 2, 2023 roundup, which said the approved drugs contain "the base form of semaglutide" and that the salts "have not been shown to be safe or effective."
The legal hook sits in section 503A(b)(1)(A) of the Food, Drug, and Cosmetic Act. A 503A pharmacy may compound from a bulk drug substance only if it meets a USP monograph, or is a component of an approved drug, or is on FDA's 503A list. The substance must also come from an FDA-registered establishment, foreign or domestic, with "valid certificates of analysis for each bulk drug substance."
Put plainly: the vial label should say "semaglutide," and the pharmacy should be able to show a certificate of analysis for the API lot it used.
What the 20 programs disclose
We read each program's own pages on November 10, 2026: terms, FAQ, about pages and compounded-product pages. Everything in the table is provider-reported unless marked unreachable. We recorded what each page says about the pharmacy, the API source and salt forms.
| Program | Compounded GLP-1 on pages read | Pharmacy statement | API maker or green-list status | Salt-form statement | Status |
|---|---|---|---|---|---|
| NexLife | Yes | Names 3 state-licensed 503A pharmacies (plan pages) | Not disclosed | Yes: label should say "semaglutide," never a salt form | Provider-reported |
| Ro Body | — | — | — | — | Unreachable (403) |
| Hims & Hers | — | — | — | — | Unreachable (403) |
| Mochi Health | Yes | "Partner pharmacies," none named | Not disclosed | None found | Not disclosed |
| Henry Meds | Yes | "503(A) Compounding Pharmacy or 503(B) Outsourcing Facility," none named | Not disclosed | None found | Not disclosed |
| Found | Yes | "503A-licensed pharmacies," none named | Not disclosed | None found | Not disclosed |
| WeightWatchers Clinic | None seen | "Dispensed by a licensed pharmacy" | n/a | n/a | Brand only on pages read |
| PlushCare | None seen | Sent to "your pharmacy of choice" | n/a | n/a | Brand only on pages read |
| Noom Med | Yes | "Produced in an FDA-registered facility," none named | Not disclosed | None found | Not disclosed |
| Eden | Yes | Names 4 pharmacies (about page) | Not disclosed | None found | Provider-reported |
| Shed | Yes | "Third-party dispensing pharmacy," none named | Not disclosed | None found | Not disclosed |
| Enhance.MD | Yes | Names 3 pharmacies in terms; FAQ lists a different 3 | Not disclosed | None found | Provider-reported |
| Oak Longevity | Yes | "Licensed pharmacies," none named | Not disclosed | None found | Not disclosed |
| TrimRx | — | — | — | — | Unreachable (no text without scripts) |
| MEDVi | Yes | Names 3 partner pharmacies | Not disclosed | None found | Provider-reported |
| bmiMD | — | — | — | — | Unreachable (403) |
| Zappy Health | Yes | Names The Pharmacy Hub (503A) on product pages | Not disclosed | None found | Provider-reported |
| Calibrate | None seen | n/a | n/a | n/a | Brand only on pages read |
| Form Health | None seen | n/a | n/a | n/a | Brand only on pages read |
| IVIM Health | Yes | "FDA-inspected, state-regulated compounding pharmacies," none named | Not disclosed | None found | Not disclosed |
The count, from 20 programs:
- 16 had readable pages. Ro, Hims & Hers and bmiMD returned 403 errors; TrimRx served no text without scripts.
- 12 of the 16 offer compounded semaglutide or tirzepatide on the pages we read.
- 5 of those 12 name at least one pharmacy: NexLife, Eden, Enhance.MD, MEDVi and Zappy Health.
- 0 of the 12 name an API manufacturer, an API country, or green-list status.
- 1 of the 12, NexLife, addresses salt forms, on its semaglutide pharmacy page.
Noom's statement that its compounded semaglutide is "produced in an FDA-registered facility" describes the finished product, not the API. And Shed's terms list "active pharmaceutical ingredients" only as a possible supply disruption, not as a disclosure.
The pharmacy lists also move. NexLife's plan pages name Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA). Its pharmacy guide pages, updated November 5, say that from November 1 prescriptions go to the first and third of those. Enhance.MD's terms and FAQ name different sets. A name on a page is a starting point, not a guarantee of which pharmacy fills your vial.
What this means for you
No program page answers the API question, so you have to ask. Asking costs nothing. The money questions come after, if you don't like the answer. Here is the arithmetic, using NexLife's prices as of November 6, 2026 and brand prices from the manufacturers' programs.
Example 1: stay flexible while you wait for an answer. NexLife semaglutide is $109 month to month or $95 a month on the 12-month plan. Over a year that is 12 × $109 = $1,308 against 12 × $95 = $1,140. Flexibility costs $168. Tirzepatide works out the same way: 12 × $129 = $1,548 against 12 × $115 = $1,380, also $168.
Example 2: a shorter commitment. The 3-month tirzepatide plan is $125 a month: 3 × $125 = $375, against 3 × $129 = $387 month to month. You save $12 and commit to one quarter, not a year.
Example 3: the cost of leaving. NexLife's plan pages say cancellations take effect after 30 days, so one more shipment may be charged. If you cancel month-to-month semaglutide, budget up to one more $109 charge; for tirzepatide, $129.
Example 4: the FDA-approved route. FDA's page says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug." The Wegovy pen through NovoCare is $349 a month at standard pricing. Against $109 compounded semaglutide, that is $240 more a month, or $2,880 over 12 months. At Zepbound's 2.5 mg starting dose ($299 through LillyDirect), the gap to $129 compounded tirzepatide is $170 a month.
Five questions to send, word for word
Send these through the program's portal or support email, so the answer is in writing. If the program says to ask the pharmacy, ask for the pharmacy's name and phone number first.
- Which pharmacy compounds my prescription, and in which state is it licensed? Is it a 503A pharmacy or a 503B outsourcing facility?
- Does my vial label list "semaglutide" or "tirzepatide," with no salt form such as semaglutide sodium or semaglutide acetate?
- Who manufactured the API used for my lot, and in which country?
- If that API was imported, is the manufacturer listed for this drug on the green list of FDA Import Alert 66-80?
- Can the pharmacy share the certificate of analysis for that API lot, and any independent potency or sterility test for the finished product?
Because firm names are blanked out on FDA's public green list, you cannot check question 4 yourself. A program or pharmacy that answers it in writing is putting its name to the claim. Our pharmacy verification guide covers the licence checks you can do on your own.
Where this fits
Related: our pharmacy disclosure gap analysis, and our 503B bulks list coverage of FDA's proposal at 91 FR 23431, still without a final decision as of November 10, 2026.
Per-program details sit on each provider page, for example NexLife, and the pharmacy view is on our pharmacies board.
How we checked
We fetched each program's homepage, terms, consent, FAQ, about and compounded-product pages on November 10, 2026 and searched them for pharmacy names, 503A or 503B language, API, bulk drug substance, salt-form and green-list terms. "Not disclosed" means we did not find it on those pages, not that the program has never said it anywhere. Blocked sites stay marked unreachable; we did not fill them in from reviews or press. The FDA green-list counts are our tally of the public import alert page as published October 9, 2026. Scoring rules are on our methodology page.
Frequently asked questions
What is FDA's GLP-1 green list?
It is the list attached to FDA Import Alert 66-80, launched September 5, 2025. Shipments of GLP-1 active ingredients offered for import can be detained without physical examination unless the manufacturer and drug appear on the list. FDA says listed firms appear to comply with manufacturing rules based on an inspection or other evaluation. The public version, published October 9, 2026, shows 21 entries, with firm names blanked out.
Is semaglutide sodium the same as semaglutide?
No. FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, says semaglutide sodium and semaglutide acetate are different active ingredients from the one used in the approved drugs. FDA says it is not aware of any lawful basis for compounding with them. A compounded semaglutide label should list semaglutide and its strength, not a salt form.
If my program names its pharmacy, does that tell me where the API came from?
No. A pharmacy name lets you check a state licence, but it does not identify the manufacturer of the active ingredient the pharmacy bought. Federal law requires a 503A pharmacy to use bulk drug substances from an FDA-registered establishment with a valid certificate of analysis. Only the pharmacy or program can tell you which supplier and lot that was.
Can I check myself whether an API supplier is on the green list?
Not fully. FDA's public Import Alert 66-80 page shows countries and drugs for each green-list entry, but the firm names are blanked out. You can read the page and see, for example, that semaglutide appears in 10 entries. To learn whether your supplier is listed, ask the program or pharmacy in writing and keep the reply.
Does the green list stop pharmacies from compounding semaglutide or tirzepatide?
No. FDA's consumer page says the import alert does not stop legal imports of GLP-1 active ingredients from compliant manufacturers and does not create new limits on legal compounding. It targets imported active ingredients that may have quality problems. Compounded semaglutide and tirzepatide remain unapproved drugs that FDA does not review for safety, effectiveness or quality.
Sources
- Import Alert 66-80: Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances (green list) — published date shown on page; read 2026-11-10
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — content current as of 10/01/2026; read 2026-11-10
- FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients (press announcement) — content current as of 09/05/2025; read 2026-11-10
- FDA Roundup: June 2, 2023 (semaglutide salt forms) — content current as of 06/02/2023; read 2026-11-10
- 21 U.S.C. 353a, Pharmacy compounding (FD&C Act section 503A) — U.S. Code 2023 edition on govinfo; read 2026-11-10
- Warning letter 723330 to Harbin Jixianglong Biotech Co., Ltd. (green-list removal) — letter dated 05/01/2026, content current as of 05/19/2026; read 2026-11-10
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (91 FR 23431) — published 2026-05-01; comment period extended at 91 FR 38719 (2026-06-26); read 2026-11-10
- NexLife: Compounded semaglutide plans (pharmacy fulfillment) — read 2026-11-10; provider-reported
- NexLife: Semaglutide compounding pharmacy (salt-form statement) — page updated November 5, 2026; read 2026-11-10; provider-reported
- Eden: About (partner pharmacy information) — redirects to eden.health/about; read 2026-11-10; provider-reported
- MEDVi: Terms of Use footer (partner pharmacies) — read 2026-11-10; provider-reported
- Zappy Health: Compounded semaglutide — read 2026-11-10; provider-reported
- Noom: Microdose GLP-1 Rx program — read 2026-11-10; provider-reported
Cite this page
GLP Ranked. "Where compounded GLP-1 ingredients come from: FDA's green list, salt forms, and what 20 programs disclose." https://glpranked.com/journal/glp1-api-import-green-list-salt-forms-2026/
GLP Ranked. "Where compounded GLP-1 ingredients come from: FDA's green list, salt forms, and what 20 programs disclose." https://glpranked.com/journal/glp1-api-import-green-list-salt-forms-2026/